Blood conservation strategies in cardiac surgery

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 7, Issue 2, 2003, Pages 175-188

  Karski, Jacek M ^a,c   Balatbat, Joselito T ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF LOUISVILLE HOSPITAL   (United States)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; ANTITHROMBOCYTIC AGENT; APROTININ; DESMOPRESSIN; DIASPIRIN CROSSLINKED HEMOGLOBIN; HEMOGLOBIN; PERFLUORO COMPOUND; PERFLUOROOCTYL BROMIDE; PLACEBO; POLYMERIZED HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; TRANEXAMIC ACID;

AGING; ANEMIA; AORTA DISSECTION; BLEEDING; BLOOD AUTOTRANSFUSION; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; BODY WEIGHT; CARDIOPULMONARY BYPASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SURGERY; CELL SAVER TECHNIQUE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; HEMODILUTION; HUMAN; KIDNEY FAILURE; LIVER DISEASE; META ANALYSIS; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PLASMAPHERESIS; PREOPERATIVE TREATMENT; REVIEW; SEPSIS; SHED BLOOD SALVAGE; SIDE EFFECT; STROKE; THROMBOSIS;

EID: 0042338735     PISSN: 10892532     EISSN: None     Source Type: Journal    
DOI: 10.1177/108925320300700206     Document Type: Review

References (111)

1. Goodnough LT, Soegiarso W, Birlmeier JD, Welch HG: The economic impact of inappropriate blood transfusion in coronary artery bypass graft surgery. Am J Med 94:509-514, 1993.
2. Johnson RG, Thurer RL, Kruskall MS: Comparison of two transfusion strategies after elective operations for myocardial revascularization. J Thorac Cardiovasc Surg 104:307-314, 1992.
3. Goodnough T, Johnston MD, Ramsey MD: Guidelines for transfusion support in patients undergoing coronary artery bypass grafting. Ann Thorac Surg 50:675-683, 1990.
4. Crosby E, for Expert Working Group: Guidelines for red blood cell and plasma transfusion for adults and children. Can Med Assoc J 156(suppl 11): 1997.
5. Stover EP, Siegel LC, Parks R: Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines. Anesthesiology 88:327-333, 1998.
6. Belisle S, Hardy JF. Hemorrhage and the use of blood products after adult cardiac operations: Myths and realities. Ann Thorac Surg 62:1908-1917, 1996.
7. Scott WJ, Kessler R, Wernly JA: Blood conservation in cardiac surgery. Ann Thorac Surg 50:843-851, 1990.
8. Hardy JF, Belisle S, Janvier G: Reduction in requirements for allogeneic blood products: Nonpharmacologic methods. Ann Thorac Surg 62:1935-1943, 1996.
9. Janssens M, Hartstein G, David JL: Reduction in requirements for allogeneic blood products: Pharmacologic Methods. Ann Thorac Surg 62:1944-1950, 1996.
10. Karski JM, Matthieu M, Cheng D: Etiology of preoperative anemia in patients undergoing scheduled cardiac surgery. Can J Anesth 46:979-982, 1999.
11. Dacey LJ, Munoz JJ, Baribeau YR: Reexploration for hemorrhage following coronary artery bypass grafting: Incidence and risk factors. Northern England Cardiovascular Disease Study Group. Arch Surg 133:442-447, 1998.
12. Talamonti MS, LoCicero J III, Hoyne WP: Early re-exploration for excessive postoperative bleeding lowers wound complication rates in open heart surgery. Am Surg 53:102-104, 1987.
13. Karski JM, Teasedale SJ, Norman P: Prevention of post bypass bleeding with tranexamic acid and ε-aminocaproic acid. J Cardiothorac Vasc Anesth 7:431-435, 1993.
14. Karski JM, Joiner R, Carroll J: Comparison of the effect of 3 different doses of tranexamic acid on postoperative bleeding in cardiac surgery performed without active systemic cooling. Society of Cardiovascular Anesthesiologists Annual Meeting, Montreal, 1994, p XX.
15. Karski JM, Teasedale SJ, Norman P: Prevention of postcardiopulmonary bypass bleeding with high dose tranexamic acid: Double-blinded, randomized clinical trial. J Thorac Cardiovasc Surg 110:835-842, 1995.
16. Holloway DS, Summaria L, Sandesara J: Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients. Thromb Haemost 59:62-67, 1988.
17. Mammen EF, Koets MH, Washington BC: Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemost 11:281-292, 1985.
18. Kestin AS, Valeri R, Khuri SF: The platelet function defect of cardiopulmonary bypass. Blood 82:107-117, 1993.
19. Cramer EM, Lu H, Caen J: Differential redistribution of platelet glycoproteins Ib and IIb-IIIa after plasmin stimulation. Blood 77:694-699,1991.
20. Lu H, Soria C, Crammer EM: Temperature dependence of plasmin-induced activation or inhibition of human platelets. Blood 77:996-1005, 1991.
21. Lu H, Soria C, Soria J: Reversible translocation of glycoprotein Ib in plasmin-treated platelets: Consequences for platelet function. Eur J Clin Invest 23:785-793, 1993.
22. Magovern JA, Sakert T, Benckart DH: A model for predicting transfusion after coronary artery bypass grafting. Ann Thorac Surg 61:27-32, 1996.
23. Ferraris VA, Gildengorin V: Predictors of excessive blood use after coronary artery bypass grafting. A multivariate analysis. J Thorac Cardiovasc Surg 98:492-497, 1989.
24. Ferraris VA, Ferraris SP: Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting (update). Ann Thorac Surg 59:1036-1037, 1995.
25. Gammie JS, Zenati M, Kormos R: Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Ann Thorac Surg 465-469, 1997.
26. Despotis GJ, Skubas NJ, Goodnough TG: Optimal management of bleeding and transfusion in patients undergoing cardiac surgery. Sem Thorac Cardiovasc Surg 11:84-104, 1999.
27. Helm RE, Rosengart TK, Gomez M: Comprehensive multimodality blood conservation: 100 consecutive CABG operations without transfusion. Ann Thorac Surg 65:125-136, 1998.
28. Pinkerton PH: Autologous blood donation in support of cardiac surgery: A preliminary report on a hospital based autologous program. Can J Anesth 41:1036-1040, 1994.
29. Ferguson D, Blair A, Henry D: Technologies to minimize blood transfusion in cardiac and orthopedic surgery. Results of a practice variation survey in nine countries. Int J Technology Assessment in Health Care 15:717-728, 1999.
30. Etchason J, Petz L, Keller E: Cost effectiveness of preoperative blood donations. N Engl J Med 332:719-724, 1995.
31. American Society of Anesthesiologists Task Force on Blood Component Therapy: Practice guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 84:732-747, 1996.
32. Gillon J, Thomas MJG, Desmond MJ: Consensus conference on autologous transfusion. Acute normovolemic hemodilution. Transfusion 36:640-643, 1996.
33. Trouwborst A, van Bommel J: Monitoring normovolemic hemodilution. Br J Anaesth 81 (suppl): 73-78, 1998.
34. Ovrum E, Holen EA, Tangen G: Consistent non-pharmacological blood conservation in primary and reoperative coronary artery bypass grafting. Eur J Cardiothorac Surg 9:30-35, 1995.
35. Schonberger JPAM, Bredee JJ, Tjian D: Intraoperative predonation contributes to blood saving. Ann Thorac Surg 56:893-898, 1993.
36. Bryson GL, Laupacis A, Wells GA: Does acute normovolemic hemodilution reduce perioperative allogeneic transfusion? A meta-analysis. Anesth Analg 86:9-15, 1998.
37. Parolari A, Antona C, Rona P: The effects of multiple blood conservation techniques on donor blood exposure in adult coronary and valve surgery performed with a membrane oxygenator: A multivariate analysis on 1310 patients. J Card Surg 10:227-235, 1995.
38. Helm RE, Klemperer JD, Rosengart TK: Intraoperative autologous blood donation preserves red cell mass but does not decrease postoperative bleeding. Ann Thorac Surg 62:1431-1441, 1996.
39. British committee for standards in hematology blood transfusion task force: In Napier JAF, Bruce M, Chapman J: Guidelines for autologous transfusion. II Perioperative hemodilution and cell salvage. Br J Anaesth 78:768-771, 1997.
40. Wells DG, Davies GG: Platelet salvage in cardiac surgery. J Cardiothorac Vasc Anesth 7:448-451, 1993.
41. Armellin G, Sorbara C, Bonato R, et al: Intraoperative plasmapharesis in cardiac surgery. J Cardiothorac Vasc Anesth 11:13-17, 1997.
42. Boldt J: Acute platelet rich plasmapheresis for cardiac surgery. J Cardiothorac Vasc Anesth 9:79-88, 1995.
43. Schonberger JPAM, van Oeveren W, Bredee JJ: Systemic blood activation during and after autotransfusion. Ann Thorac Surg 57:1256-62, 1944.
44. Morris JJ, Tan YS: Autotransfusion: Is there a benefit in current practice of aggressive blood conservation? Ann Thorac Surg 62:1935-1943, 1996.
45. Dietrich W: Pro: Shed mediastinal blood retransfusion should be used routinely in cardiac surgery. J Cardiothorac Vasc Anesth 9:95-99, 1995.
46. Body SC, Birmingham J, Parks R: Safety and efficacy of shed mediastinal blood transfusion after cardiac surgery: A multicentre observational study. Multicentre study of perioperative ischemia research group. J Cardiothorac Vasc Anesth 13:410-416, 1999.
47. Nguyen DM, Gilfix BM, Dennis F: Impact of transfusion of mediastinal shed blood on serum levels of cardiac enzymes. Ann Thorac Surg 62:109-114, 1996.
48. Peters DC, Noble S: Aprotinin: An update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery. Drugs 57:233-260, 1999.
49. Greilich PE, Okada K, Latham P: Aprotinin but not epsilon-aminocaproic acid decreases interleukin-10 after cardiac surgery with extracorporeal circulation. Circulation 104(suppl):I-265-269, 2001.
50. Poullis M, Manning R, Laffan M: The antithrombotic effect of aprotinin: Actions mediated via the protease activated receptor-1. J Thorac Cardiovasc Surg 120:370-378, 2000.
51. Soslau G, Horrow J, Brodsky I: Effect of tranexamic acid on platelet ADP during extracorporeal circulation. Am J Hemat 38:113-119, 1991.
52. Huang H, Ding W, Su Z: Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery. J Thorac Cardiovasc Surg 11-18, 1993.
53. Bidstrup BP, Royston D, Sapsford RN: Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 97:364-372, 1989.
54. Baele PL, Ruiz-Gomez J, Londot C: Systemic use of aprotinin in cardiac surgery: Influence on total homologous exposure and hospital cost. Acta Anaesthesiol Belg 43:103-112, 1992.
55. Havel M, Teufelsbauer H, Knobl P: Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. J Thorac Cardiovasc Surg 101:968-972, 1991.
56. Vedrinne C, Girard C, Jegaden O: Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin versus autologous fresh whole blood transfusion. J Cardiothorac Vasc Anesth 6:319-323, 1992.
57. Harder MP, Eijsman L, Roozendaal KJ: Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. Ann Thorac Surg 51:936-941, 1991.
58. Lemmer JH, Stanford W, Bonney SL: Aprotinin for coronary bypass operations: Efficacy, safety, and influence on early saphenous vein graft patency. J Thorac Cardiovasc Surg 107:543-553, 1994.
59. Swart MJ, Gordon PC, Hayse-Gregson PB: High-dose aprotinin in cardiac surgery: A prospective, randomized study. Anaesth Intensive Care 22:529-533, 1994.
60. Rich JB: The efficacy and safety of aprotinin use in cardiac surgery. Ann Thorac Surg 66:S6-11, 1998.
61. Royston D, Bidstrup BP, Taylor KM: Effect of aprotinin on need for blood transfusion after repeat open heart surgery. Lancet 2:1289-1291, 1987.
62. Dietrich D, Barankay A, Hanel C: High dose aprotinin in cardiac surgery: Three years' experience in 1,784 patients. J Cardiothorac Vasc Anesth 6:324-327, 1992.
63. Royston D: High-dose aprotinin therapy: A review of the first five years' experience. [Review] J Cardiothorac Vasc Anesth 6:76-100, 1992.
64. Bidstrup BP, Harrison J, Royston D: Aprotinin therapy in cardiac operations: A report on the use in 41 centres in the United Kingdom. Ann Thorac Surg 55:971-976, 1993.
65. Levi M, Cromheecke ME, de Jonge E: Pharmacological strategies to decrease excessive blood loss in cardiac surgery: A meta-analysis of clinically relevant end points. Lancet 354:1940-1947, 1999.
66. Cosgrove DM, Heric B, Lytle BW: Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study. Ann Thorac Surg 54:1031-1038, 1992.
67. Liu B, Belboul A, Radberg G: Effect of reduced aprotinin dosage on blood loss and use of blood products in patients undergoing cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg 27:149-155, 1993.
68. Hardy JF, Desroches J, Belisle S: Low dose aprotinin infusion is not clinically useful to reduce bleeding and transfusion of homologous blood products in high-risk cardiac surgical patients. Can J Anesth 40:625-631, 1993.
69. Covino E, Pepino P, Iorio D: Low dose aprotinin as blood saver in open heart surgery. Eur J Cardiothorac Surg 5:414-418, 1991.
70. Gschossmann J, Pracki P, Struck E: Efficacy of aprotinin in different doses and autologous blood transfusions in cardiac surgery. Cardiovasc Surg 2:716-719, 1994.
71. Hardy JF, Belisle S, Couturier A: Randomized, placebo-controlled, double-blind study of an ultra-low-dose aprotinin regimen in reoperative and/or complex cardiac operations. J Card Surg 12:15-22, 1997.
72. Nuttall GA, Fass DN, Oyen LJ: A study of a weight-adjusted aprotinin dosing schedule during cardiac surgery. Anesth Analg 94:283-289, 2002.
73. Levy JH, Bailey JM, Salmenpera M: Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology 80:1013-1018, 1994.
74. Tatar H, Cicek S, Demirkilic U: Topical use of aprotinin in open heart operations. Ann Thorac Surg 55:659-661, 1993.
75. O'Regan DJ, Giannopoulos N, Mediratta N: Topical aprotinin in cardiac operations. Ann Thorac Surg 58:778-781, 1994.
76. Cicek S, Theodoro DA: Topical aprotinin in cardiac operations: A note of caution. Ann Thorac Surg 61:103-104, 1996.
77. Hayashida N, Isomura T, Sato T: Effects of minimal-dose aprotinin on coronary artery bypass grafting. J Thorac Cardiovasc Surg 114:261-269, 1997.
78. Proud G, Chamberlain J: Anaphylactic reaction to aprotinin. Lancet 2:48-49, 1976.
79. Dewachter P, Mouton C, Masson C: Anaphylactic reaction to aprotinin during cardiac surgery. Anaesthesia 48:1110-1111, 1993.
80. Regoli D, Barabe J: Pharmacology of bradykinin and related kinins. Pharmacol Rev 32:1-46, 1980.
81. Proud D, Kaplan AP: Kinin formation: Mechanisms and role in inflammatory disorders. Annu Rev Immunol 6:49-83, 1988.
82. Schweizer A, Hohn L, Morel DR: Aprotinin does not impair renal hemodynamics and function after cardiac surgery. Br J Anaesth 84:16-22, 2000.
83. Maineri P, Covaia G, Realini M: Postoperative bleeding after coronary revascularization. Comparison between tranexamic acid and epsilon-aminocaproic acid. Minerva Cardioangiol 48:155-160, 2000.
84. Fremes SP, Wong BI, Lee E: Meta-analysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 58:1580-1588, 1994.
85. Jansen AJ, Andreica S, Claeys M: Tranexamic acid and blood conservation strategy after total knee arthroplasty. Br J Anaesth 83:596-601, 1999.
86. Miyashita T, Kamibayashi T, Ohnishi Y: Preservation of collagen-induced whole blood platelet aggregation by tranexamic acid in primary cardiac valve surgery. Perfusion 15:507-513, 2000.
87. Horrow JC, Van Riper DF, Strong MD: Haemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation 85:2063-2070, 1991.
88. Horrow JC, Hlavacek J, Strong MD: Prophylactic tranexamic acid decreases bleeding after cardiac operations. J Thorac Cardiovasc Surg 99:70-74, 1990.
89. Casati V, Bellotti F, Gerli C: Tranexamic acid administration after cardiac surgery: A prospective randomized, double-blind, placebo-controlled study. Anesthesiology 94:8-14, 2001.
90. DelRossi AJ, Cernaianu AC, Botros S: Prophylactic treatment of postperfusion bleeding using EACA. Chest 96:27-30, 1989.
91. Hardy JF, Belisle S: Natural and synthetic antifibrinolytics in adult cardiac surgery: Efficacy, effectiveness and efficiency. [Review] Can J Anesth 41:1104-1112, 1994.
92. Munoz JJ, Birkmeyer NJO, Birkmeyer JD: Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery? A meta-analysis. Circulation 99:81-89, 1999.
93. Isetta C, Samat C, Lugrin D: Tranexamic acid is as effective as aprotinin in reducing blood loss and blood requirements after CPB for cardiac surgery in routine patients. Anesth Analg S1-S581, S206, 1980.
94. Havel M, Grabenvoger F, Schneider J: Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg 107:807-810, 1994.
95. Bidstrup BP, Underwood SR, Sapsford RN: Effect of aprotinin (Trasylol) on aorto-coronary bypass graft patency. J Thorac Cardiovasc Surg 105:148-153, 1993.
96. Alderman EL, Levy JH, Rich JB: Analyses of coronary graft patency after aprotinin use: Results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg 116:716-730, 1998.
97. Sheridan DP, Card RT, Pinilla JC: Use of desmopressin acetate to reduce blood transfusion requirements in patients with acetylsalicylic-acid-induced platelet dysfunction. Can J Surg 37:33-36, 1994.
98. Laupacis A: Drugs to minimize perioperative blood loss in cardiac surgery: Meta-analysis using perioperative blood transfusion as the outcome. The International Study of Perioperative Transfusion Investigators. Anesth Analg 85:1258-1267, 1997.
99. Cattaneo M, Harris A, Stromberg U: The effect of Desmopressin on reducing blood loss in cardiac surgery - A meta-analysis of double-blind, placebo controlled trials. Thromb Hemost 74:1064-1070, 1995.
100. Wong BI, McLean RF, Fremes SE: Aprotinin and tranexamic acid for high transfusion risk cardiac surgery. Ann Thorac Surg 69:808-816, 2000.
101. Casati V, Guzzon D, Oppizzi M: Tranexamic acid compared with high dose aprotinin in primary elective heart operations: Effects on perioperative bleeding and allogeneic transfusions. J Thorac Cardiovasc Surg 120:520-527, 2000.
102. Kiyama H, Ohshima N, Imazeki T: Autologous blood donation with recombinant human erythropoietin in anemic patients. Ann Thorac Surg 68:1652-1656, 1999.
103. Coyle D, Lee KM, Fergusson DA: Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery. Pharmacoeconomics 18:161-171, 2000.
104. Sowade D: Avoidance of allogeneic blood transfusions by treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing open heart surgery. Blood 89:411, 1997.
105. Spahn DR, Leone BJ, Reves JG: Cardiovascular and coronary physiology of acute isovolemic hemodilution: A review of non-oxygen carrying and oxygen carrying solutions. Anesth Analg 78:1000-1021, 1994.
106. Dietz NM, Joyner MJ, Warner MA: Blood substitutes: Fluids drugs or miracle solutions? [Review]. Anesth Analg 82:390-405, 1996.
107. Cheng DCH: Safety and efficacy of o-raffinose cross-linked human hemoglobin (Hemolink™) in cardiac surgery. Can J Anesth 48:S41-48, 2001.
108. Hebert PC, Wells G, Martin C: Variation in red cell transfusion practice in the intensive care unit: A multicentre cohort study. Crit Care 3:57-63, 1999.
109. Hebert PC, Szick S: Transfusion in the intensive care unit: Strategies under scrutiny. Curr Opin Anesthesiol 13:119-123, 2000.
110. Goodnough LT: Transfusion medicine. N Engl J Med 340:525-533, 1999.
111. Scott WJ, Rode R, Castlemain B: Efficacy, complications, and cost of a comprehensive blood conservation program for cardiac operations. J Thorac Cardiovasc Surg 103:1001-1006; Discussion 1006-1007, 1992.